Colorado Center for Bone Research

Recent papers from Colorado Center for Bone Research

1. Real-world treatment patterns and clinical outcomes among US patients with non-muscle invasive bladder cancer (NMIBC) during the BCG shortage.Journal of Clinical Oncology · 2026
2. Mineral, Bone, and Cardiovascular Disorders in CKD: The Case for a New ParadigmKidney Medicine · 2026
3. Osteoporosis and CKD-Metabolic Bone Disease Under the Same Umbrella: Insights From a Joint Scientific SymposiumKidney International Reports · 2026
4. The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney diseaseJournal of Nephrology · 2023
5. The role of osteoanabolic agents in the management of patients with osteoporosisPostgraduate Medicine · 2022
6. Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone DiseasesJournal of Clinical Densitometry · 2021
7. Burosumab for the Treatment of Tumor-Induced OsteomalaciaJournal of Bone and Mineral Research · 2020
8. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney DiseaseJournal of Bone and Mineral Research · 2020
9. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With OsteoporosisJournal of Bone and Mineral Research · 2020
10. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney DiseaseThe Journal of Clinical Endocrinology & Metabolism · 2020
11. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosisCurrent Medical Research and Opinion · 2020
12. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its ManagementJournal of Bone and Mineral Research · 2020
13. Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE StudyJBMR Plus · 2020
14. Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its ManagementJournal of Bone Metabolism · 2020
15. Macrocyclic polyamine [12]aneN ₃ modified triphenylamine-pyrazine derivatives as efficient non-viral gene vectors with AIE and two-photon imaging propertiesJournal of Materials Chemistry B · 2020
16. Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtendBone Reports · 2019
17. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trialCurrent Medical Research and Opinion · 2019
18. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over groupOsteoporosis International · 2019
19. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab TreatmentThe Journal of Clinical Endocrinology & Metabolism · 2019
20. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosisOsteoporosis International · 2019